Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes:
MetablokTM, a potential treatment for inflammation, sepsis and cancer metastasis - in Phase II international trials;
AB569, a potential new treatment for antibiotic resistant bacterial infections;
‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics; and,
MetaMxTM, which targets elusive brain tumor initiating cells.